<DOC>
	<DOCNO>NCT01076920</DOCNO>
	<brief_summary>Ischemic cardiomyopathy lead cause death men woman . When person heart attack , blood unable reach certain area heart , blood supply re-established quickly , area heart suffer permanent damage . While recovery heart attack manage medication lifestyle change , treatment reverse damage heart . Current research focus development cell-based therapy use stem cell repair organ irreversibly damage disease . A specific form stem cell , call adult mesenchymal stem cell ( MSCs ) , show promise heart repair . This study evaluate safety inject MSCs directly heart repair restore heart function people heart attack chronic myocardial ischemia heart failure .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Myocardial Ischemia</brief_title>
	<detailed_description>Mesenchymal stem cell bone marrow differentiate endothelial cell participate development new blood vessel ischemic tissue . The aim study phase I safety study evaluate clinical effect autologous mesenchymal stem cell therapy patient severe chronic myocardial ischemia.10 patient reversible ischemia SPECT treat direct intramyocardial injection autologous isolate expanded mesenchymal stem cells.Clinical objective evaluation perform baseline 24 month follow-up .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>1 . Age 18 75 2 . Male female 3 . NYHA ( Heart failure ) Class IIIV Angina pectoris CCS Class III IV symptom consistent ) 4 . Chronic coronary artery disease leave ventricular function 35 % 5 . Stable medical therapy least one month 6 . Reversible perfusion defect SPECT 7 . Not candidate coronary artery bypass surgery due poor target small vessel candidate percutaneous intervention due small vessel unreachable coronary lesion due complicate anatomy 8 . Implantable Cardiovertor Defibrillator 1 . Acute coronary syndrome , revascularization ( PCI CABG ) , cardiac resynchronization last 3 month 2 . Sustained ventricular 3 . Further revascularization plan next 30 day . 4 . Chronic atrial fibrillation . 5 . A wall thickness target region &lt; 8 mm determine 2D echocardiography ( target region defined time NOGAÂ® mapping ) . 6 . An LV thrombus . 7 . Severe peripheral vascular disease preclude femoral artery access determine time original catheterization . 8 . Aortic stenosis determine valve area le 1 cm2 prohibits catheter access LV . 9 . Human immunodeficiency virus ( HIV12 ) , HTLV1 2 . 10 . An active uncontrolled infection . 11 . A prosthetic aortic valve . 12 . A current prior history within last 3 year neoplasm ( exclude basal cell ) and/or active neoplasm within last 24 month . 13 . Pregnancy breastfeed . 14 . Active participation research therapy cardiovascular repair/regeneration . 15 . Any medical condition would affect investigator 's ability evaluate subject 's condition could compromise subject 's safety . 16 . Any condition , judgment investigator , would prohibit subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>